### Tab 1: Pharmaceutical Compliance & Clinical Trial Approval Rules
- High Compliance Risk Criteria: A Phase III clinical trial is classified as *High Compliance Risk* if it satisfies at least one of the following conditions: (1) more than 2 protocol amendments, or (2) a patient dropout rate strictly greater than 5.0%.
- Sign-off Requirement: If a Phase III trial is classified as *High Compliance Risk*, all quarterly reporting requires dual sign-off from both the Lead Investigator and the Independent Ethics Board (IEB). Without dual sign-off on file, the trial's reported efficacy metric is automatically suspended from board valuation.
- Emergency Exemption: Clinical trials operating under Emergency Expedited Authorization (EEA) are exempt from the dual sign-off requirement regardless of risk status, provided total patient enrollment exceeds 500.
| Trial Code | Phase | Protocol Amendments | Patient Enrollment | Patient Dropout Rate | EEA Status | Sign-off On File | Reported Efficacy |
|---|---|---|---|---|---|---|---|
| Trial-Alpha | Phase III | 3 | 600 | 4.0% | Yes | Lead Investigator Only | 84% |
| Trial-Beta | Phase III | 1 | 400 | 6.2% | No | Lead Investigator & IEB | 91% |
| Trial-Gamma | Phase II | 4 | 250 | 8.0% | Yes | Lead Investigator Only | 78% |
| Trial-Delta | Phase III | 2 | 550 | 5.5% | No | Lead Investigator Only | 88% |
### Tab 3: Board Valuation Standards
- To be included in the Q3 R&D pipeline valuation as Pipeline Qualified, a trial must be a Phase III trial, must have a valid (non-suspended) reported efficacy metric under Tab 1 rules, and must achieve a reported efficacy of at least 85%.
Statement for Evaluation:
Based on the information provided across all three tabs, evaluate whether the following statement is True or False:
"Exactly two of the four audited trials (Trial-Alpha, Trial-Beta, Trial-Gamma, Trial-Delta) meet all criteria to be classified as 'Pipeline Qualified' for the Q3 R&D pipeline valuation."
Cevap: Cevap